Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 144NIH 8NETWORK 7OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Capecitabine 6Bevacizumab 5Oxaliplatin 4Radiotherapy 3olaparib 2durvalumab 2dalpiciclib 2atezolizumab 2anlotinib 2Standard of Care 2Radiosurgery 2Leucovorin 2Laparoscopy 2Fluorouracil 2Drug Therapy 2trametinib 1toripalimab 1tislelizumab 1spartalizumab 1pyrotinib 1pomalidomide 1palbociclib 1nilotinib 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1irinotecan sucrosofate 1hetrombopag 1glasdegib 1futibatinib 1fasudil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Radiosurgery × 90 days × Clear all
NCT07293468 2026-04-09

BIIRTH

Tuen Mun Hospital

Phase 2/3 Recruiting
106 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡